Modality.AI is a venture-backed digital health startup based in San Francisco. Modality’s FDA-listed product measures CNS conditions (e.g. Parkinson’s, depression, and autism) using speech and visual analytics of conversations elicited by their virtual agent Tina. The target markets (pharma trials, remote patient monitoring, and in-clinic assessments) are multi-billion dollar markets, and Modality has shown traction in trials and with neurological assessments at clinics and remotely (including USCF, MGH, NYU, Purdue, and Charite), testing tens of thousands of people. Modality is led by a full-time team of world-class scientists, technologists, and serial entrepreneurs, and has shown clinical validation of its product in over 25 peer-reviewed publications.